Role reversal for large-cap medtechs
Shareholders are rewarding the kinds of companies they punished a year ago.
Asco 2021 – Guardant shoots for the moon
And an expanded market awaits its colorectal cancer blood test, though Exact will benefit first.
Venture-backed medtechs rush for the exit
A lot of money is sloshing around, and medical device start-ups are reaping the benefits.
Medtech’s haves and have-nots
Medtronic’s quarterly results yesterday might presage a recovery, and some groups are in dire need of one.
